Sei Investments Co. Increases Stock Holdings in Bioventus Inc. $BVS

Sei Investments Co. increased its stake in shares of Bioventus Inc. (NASDAQ:BVS) by 160.7% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 289,648 shares of the company’s stock after acquiring an additional 178,539 shares during the period. Sei Investments Co.’s holdings in Bioventus were worth $2,644,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BVS. Caitong International Asset Management Co. Ltd grew its position in Bioventus by 17,156.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Bioventus during the fourth quarter worth $80,000. Diversified Trust Co acquired a new position in shares of Bioventus during the first quarter worth $100,000. Prelude Capital Management LLC acquired a new position in shares of Bioventus during the third quarter worth $74,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Bioventus in the third quarter valued at $78,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BVS. Barrington Research set a $18.00 price target on shares of Bioventus in a report on Thursday. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Tuesday, June 16th. Weiss Ratings raised shares of Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Finally, Craig Hallum restated a “buy” rating and set a $18.00 target price on shares of Bioventus in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Bioventus has a consensus rating of “Buy” and an average target price of $16.25.

Bioventus Stock Performance

Bioventus stock opened at $14.13 on Friday. The stock has a market cap of $1.18 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 1.80 and a beta of 0.63. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 0.83. The stock has a 50 day moving average of $10.81 and a 200-day moving average of $9.69. Bioventus Inc. has a 52 week low of $6.26 and a 52 week high of $15.89.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.22. The business had revenue of $153.21 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, analysts expect that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.